VRTX Vertex Pharmaceuticals Incorporated
VRTX Vertex Pharmaceuticals Incorporated
Healthcare · Biotechnology
Market read
Scan convergence 2 scans as of 2026-08-14 2 bull converging
POC $442.25 · VWAP $445.82 · +15.6% vs 12m avg buyer
Insiders no data — outside the Form 4 poll — US-filer feed only (foreign filers report via MAR managers'-transactions notices)
Coverage
2 related perspectives
VRTX Price Structure
Loading timeframes…
Peers
Every watchlist VRTX belongs to, members best 30-day change first — VRTX highlighted in place. Each pill: 30d change, 1d/7d, and a close spark over the last 30 calendar days (~21 sessions); hover for price, RSI, and the full chart.
@biotech
@healthcare-scan
@healthcare
@ibb
@biotech-scan
@insider-universe
Reported the quarter ending 2026-03-31: revenue $2.99B, diluted EPS $4.02, net income $1.03B (SEC filing). Across the print the stock moved +0.1% (close before → first close after).
full note →Against street estimates
How VRTX's reported EPS compared with analyst consensus. Street estimates are single-source vendor consensus (yfinance). Actuals are vendor consensus-basis EPS (often non-GAAP); edgarEps is GAAP diluted from filings — disputed flags large disagreement only. EPS only.
News (last pull)
Headlines about VRTX from the desk's news pull — links go to the publisher. Not a desk read: the market read above is the desk's own.
pulled 126 days ago · Apr 14 · last pull reported an error, so these may be older than they look
- Vertex set to report Q1 2026 earnings on May 4, analysts expect EPS $4.43
- Vertex Pharmaceuticals price target raised to $612 from $596 at Morgan Stanley
- Vertex Advances FDA Filing for IgA Nephropathy Therapy
- Vertex’s VX-407 Kidney Study Completion: What Phase 1 Progress Means For VRTX Investors
- Vertex Pops On 'Remarkable' Results For Chronic Kidney Disease Drug
VRTX research tape
90 dated scans, research, and events, newest first — the full record. Desk commentary and scheduled prints sit in their own panes.